Resmetirom, a thyroid hormone beta (THR-β) agonist, has been shown to improve metabolic-dysfunction associated steatohepatitis (MASH) and fibrosis in patients with non-cirrhotic MASH in a Phase 3 serial liver biopsy study. The impact of resmetirom compared with placebo on histologic fibrosis features was evaluated using artificial intelligence (AI)-based digital pathology (qFibrosis) in the phase 3 MAESTRO-NASH trial.
Journal of Hepatology published a clinical update in Research Highlights on 25 Mar 2026.
The item focuses on Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial.
Review the original article for the full source wording and details.